Home>Topics>Stocks>Abiomed

Abiomed ABMD

  1. All
  2. Commentary
  3. Headlines
    1. UPDATE 1-FDA approves Abiomed's blood pump device

      Headlines

      Mon, 23 Mar 2015

      March 23 (Reuters) - The U.S. Food and Drug Administration said it approved Abiomed Inc's miniature blood pump system that maintains heart function and circulation during high-risk procedures.

    2. UPDATE 2- Abiomed raises revenue outlook, wins US approval for heart pump

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock up about 30...

    3. CORRECTED-UPDATE 1- Abiomed raises revenue outlook, wins US approval for heart pump

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock nearly 32...

    4. UPDATE 1- Abiomed raises revenue outlook, wins US approval for heart pump

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock nearly 32...

    5. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      Holding Market Value ($) Weight (%) Star Rating Matt's Roth IRA: Cash 5,263 1.96 N/A Matt's Roth IRA: Abiomed ABMD 184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals

    6. Dropping Coverage of Abiomed

      Commentary

      Wed, 18 Dec 2013

      We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    7. Abiomed Back on Track in 2Q, Following Weak Beginning of Fiscal Year

      Commentary

      Wed, 13 Nov 2013

      Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there

    8. Abiomed Posts Weak First Quarter, but Our Fair Value Estimate Is Unchanged

      Commentary

      Thu, 1 Aug 2013

      Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the

    9. Thoratec Delivers Strong 2Q Following Anemic 1Q

      Commentary

      Thu, 1 Aug 2013

      unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .

    10. Abiomed Sales Rise Past Estimates

      Commentary

      Wed, 17 Apr 2013

      On Wednesday, Abiomed ABMD released preliminary fourth-quarter ..... our positive moat trend rating for Abiomed . Although we do not believe the firm ..... yet, momentum continues to build for Abiomed with the U.S. release of Impella

    « Prev12345Next »
    Content Partners